The medtech startup ConKay Medical Systems, situated in Pleasanton, CA, has secured $1.8 million in seed capital.
Unorthodox Ventures, SCP Ventures, WS Investment Company, and private angel investors were among the backers.
The money will be used by the business to increase operations and development initiatives.
ConKay Medical Systems, an early-stage medical device firm led by CEO Albert Yuan, is developing methods to treat valvular regurgitation in patients suffering from progressive heart failure.
Its catheter is adaptable and addresses every existing constraint, such as preventing pacemaker leads. By putting a small implant around the annulus of the valve, the device resembles open heart surgery without requiring the patient to have their chest opened.
“Millions of Tricuspid Regurgitation patients worldwide are currently left with no medical options, and at ConKay, our mission is to help patients live longer lives with their loved ones,” Albert Yuan stated in response to the news, he continued.“ We are appreciative of our investors’ faith in us and their assistance in achieving our objective.”
In order to fund first-in-human testing, the business planned to raise its next round of funding in the second quarter of 2024.
ConKay Medical Systems
ConKay Medical Systems is an early stage medical device company advancing solutions to treat valvular regurgitation in patients with progressive heart failure.
